Evidence map›Paper›PMID 40355823›Full record

ArticleBMC infectious diseases2025

Effectiveness of Ivermectin treatment among adult patients infected with Strongyloides stercoralis in East Gojam zone, Northwest Ethiopia.

Gashaw Azanaw Amare, Yenesew Mihret Wondmagegn, Abebaw Setegn, Mekuriaw Belayneh, Yalew Muche, Abateneh Melkamu, Kassahun Misgana, Agenagnew Ashagre, Temesgen Baylie, Mohammed Jemal and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Phytomedicines and conventional drugs in scabies management.GMS hygiene and infection control · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Gashaw Azanaw AmareDepartment of Medical Laboratory Science, Debre Markos University, Debre Markos, Ethiopia. gashaw1azanaw@gmail.com.ORCID http://orcid.org/0009-0001-4803-1514
Yenesew Mihret WondmagegnDepartment of Medical Parasitology, University of Gondar, Gondar, Ethiopia.
Abebaw SetegnDepartment of Medical Parasitology, University of Gondar, Gondar, Ethiopia.
Mekuriaw BelaynehDepartment of Medical Laboratory Science, Debre Markos University, Debre Markos, Ethiopia.
Yalew MucheDepartment of Medical Laboratory Science, Debre Markos University, Debre Markos, Ethiopia.
Abateneh MelkamuDepartment of Medical Laboratory Science, Debre Markos University, Debre Markos, Ethiopia.
Kassahun MisganaDepartment of Medical Laboratory Science, Arba Minch University, Arba Minch, Ethiopia.
Agenagnew AshagreDepartment of Medical Laboratory Science, Woldia University, Woldia, Ethiopia.
Temesgen BaylieDepartment of Biomedical Science, School of Medicine, Debre Markos University, Debre Markos, Ethiopia.
Mohammed JemalDepartment of Biomedical Science, School of Medicine, Debre Markos University, Debre Markos, Ethiopia.
Mamaru GetinetDepartment of Biomedical Science, School of Medicine, Debre Markos University, Debre Markos, Ethiopia.
Abebe FentaDepartment of Medical Laboratory Science, Debre Markos University, Debre Markos, Ethiopia.
Habtamu BelewDepartment of Medical Laboratory Science, Debre Markos University, Debre Markos, Ethiopia.
Adane AdugnaDepartment of Medical Laboratory Science, Debre Markos University, Debre Markos, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionStrongyloidiasis caused by the parasite Strongyloides stercoralis, is a significant public health issue, particularly in low-income countries with inadequate sanitation practices. Ivermectin is the recommended drug by the World Health Organization for treating S. stercoralis infection, but its efficacy in Ethiopia has not been extensively studied. This study aimed to assess the effectiveness of Ivermectin treatment for S. stercoralis infection in adult patients.

methodsA cross-sectional study was conducted in government hospitals in northwest Ethiopia from June 2022 to February 2024. A total of 190 patients confirmed to be infected with S. stercoralis were treated with Ivermectin (200 µg/kg) for two days. Stool samples were collected two weeks after treatment and analyzed using parasitological concentration techniques.

resultsThe cure rate was 90% among the treated individuals, demonstrating a significant reduction in the prevalence of S. stercoralis infection. Among the cases that were not cured, the majority were older individuals, with a higher proportion (66.8%) residing in rural areas. A small number of non-cured individuals experienced persistent symptoms after treatment. All individuals who successfully cleared the infection were asymptomatic.

conclusionThe study found a 90% cure rate for the current 2-day Ivermectin treatment regimen (200 µg/kg) against Strongyloides stercoralis in Ethiopia, suggesting the recommended strategy is appropriate. Age, residential area, and other factors have been found to influence treatment outcomes, warranting further investigation into potential resistance factors and optimizing treatment for different populations.

Indexed as

Antiparasitic AgentsIvermectinStrongyloides stercoralisStrongyloidiasisAdolescentAdultAgedAnimalsCross-Sectional StudiesEthiopiaFecesFemaleHumansMaleMiddle AgedPrevalenceAntiparasitic AgentsIvermectinEfficacyEthiopiaIvermectinStrongyloidiasis

Identifiers

PMID40355823
PMCPMC12070724

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.